To study the effect of two drugs karanjadi vati and rosuvastatin tablet in patient with medovridhhi or high Cholesterol level.

Phase 2

• Conditions: Health Condition 1: E785- Hyperlipidemia, unspecified

• Registration Number: CTRI/2019/08/020739
• Lead Sponsor: ASHISH KECHE

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1)Patient having Serum LDL Cholesterol Level above 190mg/dl.

2) According to NCEP ATP III, Patient having multiple (+2) risk factor with 10 year risk of 10% of CHD whose LDL Cholesterol goals not achieve (>=160mg/dl) after 12 weeks Therapeutic lifestyle changes (TLC).

3)According to NCEP ATP III, Patient having multiple (+2) risk factor with 10 year risk of 10% to 20% of CHD whose LDL Cholesterol goals not achieve (>=130mg/dl) after 12 weeks Therapeutic lifestyle changes (TLC).

Exclusion Criteria

1)Patient with Multiple (+2) risk factor with 10 year risk 10% of CHD, who achieve the goal of LDL Cholesterol (<=160mg/dl) after TLC therapy.

2)Patient with Multiple (+2) risk factor with 10 year risk 10% to 20% of CHD, who achieve the goal of LDL Cholesterol (<=130mg/dl) after TLC therapy.

3)Pregnant women and lactating mothers.

4)Patients having history of Renal Disease, Liver Disease.

5)Patients having Recently 3 month history of Heart Failure or Stroke.

6)Patients having disorders like Carcinoma etc. anywhere in the body.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
value of LDL and signs and symptoms of hyperlipidaemia (Medovridhhi).Timepoint: 3 year

Secondary Outcome Measures

Name	Time	Method
SAFETY AND EFFICACY OF KARANJADI VATI AND ROSUVASTATIN TABLETTimepoint: 3 years